Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 25;32(8):551.
doi: 10.1007/s00520-024-08691-0.

MASCC/ISOO Clinical Practice Statement: Clinical assessment of salivary gland hypofunction and xerostomia in cancer patients

Catherine Hong  1 , Joel B Epstein  2   3 , Siri Beier Jensen  4 , Luiz Alcino Gueiros  5 , Stephanie J M van Leeuwen  6 , Abhishek Kandwal  7 , Arjan Vissink  8 , Sharon Elad  9
Affiliations
Review

MASCC/ISOO Clinical Practice Statement: Clinical assessment of salivary gland hypofunction and xerostomia in cancer patients

Catherine Hong et al. Support Care Cancer. .

Abstract

Purpose: A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS is focused on the clinical assessment of salivary gland hypofunction and xerostomia in cancer patients.

Methods: This CPS was developed based on a critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. The information is presented in the form of succinct bullets and tables to generate a short manual about the best standard of care.

Results: The objective assessment of saliva secretion involves an extra- and intra-oral clinical examination while the subjective assessment involves eliciting information on the patient's complaint of xerostomia and its impact on daily functioning. This CPS summarizes the common investigator- and patient-reported instruments used in clinical practice for assessing salivary gland hypofunction and xerostomia in cancer patients.

Conclusion: There is a range of tools to assess salivary gland function in patients undergoing cancer therapy, patients recovering from cancer therapy, or cancer survivors. Clinicians should ideally conduct both objective and subjective measurements to ensure a clear understanding about the status of the patients in order to provide the most appropriate treatment.

Keywords: Cancer; Dry mouth; Oral manifestations; Salivary gland hypofunction; Xerostomia.

PubMed Disclaimer

References

    1. Wolff A et al (2017) A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the world workshop on oral medicine VI. Drugs R D 17(1):1–28 - DOI - PubMed
    1. Jensen SB et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18(8):1039–1060 - DOI - PubMed
    1. Mercadante V et al (2021) Salivary gland hypofunction and/or xerostomia induced by nonsurgical cancer therapies: ISOO/MASCC/ASCO Guideline. J Clin Oncol 39(25):2825–2843 - DOI - PubMed
    1. Jensen SB et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 18(8):1061–1079 - DOI - PubMed
    1. Cleary N, Mulkerrin OM, Davies A (2022) Oral symptom assessment tools in patients with advanced cancer: a scoping review. Support Care Cancer 30(9):7481–7490 - DOI - PubMed - PMC

LinkOut - more resources